{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T19:44:53Z","timestamp":1775504693592,"version":"3.50.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T00:00:00Z","timestamp":1583366400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T00:00:00Z","timestamp":1583366400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100014421","name":"EA Pharma Co., Ltd.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014421","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s00774-020-01095-0","type":"journal-article","created":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T16:03:56Z","timestamp":1583424236000},"page":"501-510","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Skeletal and mineral metabolic effects of risedronate in a rat model of high-turnover renal osteodystrophy"],"prefix":"10.1007","volume":"38","author":[{"given":"Hiroaki","family":"Ishida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotaka","family":"Komaba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Hamano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Yamato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaichiro","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehiko","family":"Wada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michio","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Fukagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,5]]},"reference":[{"key":"1095_CR1","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1681\/ASN.2005111194","volume":"17","author":"TL Nickolas","year":"2006","unstructured":"Nickolas TL, McMahon DJ, Shane E (2006) Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am Soc Nephrol 17:3223\u20133232","journal-title":"J Am Soc Nephrol"},{"key":"1095_CR2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1001\/archinte.167.2.133","volume":"167","author":"KE Ensrud","year":"2007","unstructured":"Ensrud KE, Lui LY, Taylor BC, Ishani A, Shlipak MG, Stone KL, Cauley JA, Jamal SA, Antoniucci DM, Cummings SR (2007) Renal function and risk of hip and vertebral fractures in older women. Arch Intern Med 167:133\u2013139","journal-title":"Arch Intern Med"},{"key":"1095_CR3","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/ki.2013.279","volume":"85","author":"F Tentori","year":"2014","unstructured":"Tentori F, McCullough K, Kilpatrick RD, Bradbury BD, Robinson BM, Kerr PG, Pisoni RL (2014) High rates of death and hospitalization follow bone fracture among hemodialysis patients. Kidney Int 85:166\u2013173","journal-title":"Kidney Int"},{"key":"1095_CR4","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","volume":"69","author":"S Moe","year":"2006","unstructured":"Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G (2006) Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int 69:1945\u20131953","journal-title":"Kidney Int"},{"key":"1095_CR5","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","volume":"15","author":"GA Block","year":"2004","unstructured":"Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM (2004) Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15:2208\u20132218","journal-title":"J Am Soc Nephrol"},{"key":"1095_CR6","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1053\/j.ajkd.2005.09.024","volume":"47","author":"MD Danese","year":"2006","unstructured":"Danese MD, Kim J, Doan QV, Dylan M, Griffiths R, Chertow GM (2006) PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. Am J Kidney Dis 47:149\u2013156","journal-title":"Am J Kidney Dis"},{"key":"1095_CR7","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/sj.ki.5001754","volume":"70","author":"M Jadoul","year":"2006","unstructured":"Jadoul M, Albert JM, Akiba T, Akizawa T, Arab L, Bragg-Gresham JL, Mason N, Prutz KG, Young EW, Pisoni RL (2006) Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the dialysis outcomes and practice patterns study. Kidney Int 70:1358\u20131366","journal-title":"Kidney Int"},{"key":"1095_CR8","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/ki.2014.349","volume":"87","author":"G Behets","year":"2015","unstructured":"Behets G, Spasovski G, Sterling L, Goodman WG, Spiegel DM, De Broe ME, D'Haese PC (2015) Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism. Kidney Int 87:846\u2013856","journal-title":"Kidney Int"},{"key":"1095_CR9","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1681\/ASN.2014040414","volume":"26","author":"S Moe","year":"2015","unstructured":"Moe S, Abdalla S, Chertow G, Parfrey P, Block GA, Correa-Rotter R, Floege J, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Dehmel B, Goodman WG, Dr\u00fceke TB (2015) Effects of cinacalcet on fracture events in patients receiving hemodialysis: the EVOLVE trial. J Am Soc Nephrol 26:1466\u20131475","journal-title":"J Am Soc Nephrol"},{"key":"1095_CR10","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0272-6386(03)00909-0","volume":"42","author":"A Yajima","year":"2003","unstructured":"Yajima A, Ogawa Y, Takahashi H, Tominaga Y, Inou T, Otsubo O (2003) Changes of bone remodeling immediately after parathyroidectomy for secondary hyperparathyroidism. Am J Kidney Dis 42:729\u2013738","journal-title":"Am J Kidney Dis"},{"key":"1095_CR11","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1681\/ASN.2007010022","volume":"18","author":"K Rudser","year":"2007","unstructured":"Rudser K, de Boer I, Dooley A, Young B, Kestenbaum B (2007) Fracture risk after parathyroidectomy among chronic hemodialysis patients. J Am Soc Nephrol 18:2401\u20132407","journal-title":"J Am Soc Nephrol"},{"key":"1095_CR12","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1053\/j.ajkd.2013.02.368","volume":"62","author":"T Arneson","year":"2013","unstructured":"Arneson T, Li S, Liu J, Kilpatrick R, Newsome B, Peter W (2013) Trends in hip fracture rates in US hemodialysis patients, 1993\u20132010. Am J Kidney Dis 62:747\u2013754","journal-title":"Am J Kidney Dis"},{"key":"1095_CR13","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1053\/j.ajkd.2017.07.017","volume":"71","author":"M Wakasugi","year":"2018","unstructured":"Wakasugi M, Kazama J, Wada A, Hamano T, Masakane I, Narita I (2018) Hip fracture trends in Japanese dialysis patients, 2008\u20132013. Am J Kidney Dis 71:173\u2013181","journal-title":"Am J Kidney Dis"},{"key":"1095_CR14","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","volume":"282","author":"ST Harris","year":"1999","unstructured":"Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 282:1344\u20131352","journal-title":"JAMA"},{"key":"1095_CR15","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","volume":"344","author":"MR McClung","year":"2001","unstructured":"McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY (2001) Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344:333\u2013340","journal-title":"N Engl J Med"},{"key":"1095_CR16","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1359\/JBMR.050817","volume":"20","author":"PD Miller","year":"2005","unstructured":"Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE (2005) Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res 20:2105\u20132115","journal-title":"J Bone Miner Res"},{"key":"1095_CR17","first-page":"45","volume":"54","author":"Z Geng","year":"2000","unstructured":"Geng Z, Monier-Faugere MC, Bauss F, Malluche HH (2000) Short-term administration of the bisphosphonate ibandronate increases bone volume and prevents hyperparathyroid bone changes in mild experimental renal failure. Clin Nephrol 54:45\u201353","journal-title":"Clin Nephrol"},{"key":"1095_CR18","first-page":"174","volume":"5","author":"A Tomat","year":"2005","unstructured":"Tomat A, Gamba CA, Mandalunis P, De Grandi MC, Somoza J, Friedman S, Zeni S (2005) Changes in bone volume and bone resorption by olpadronate treatment in an experimental model of uremic bone disease. J Musculoskelet Nueronal Interact 5:174\u2013181","journal-title":"J Musculoskelet Nueronal Interact"},{"key":"1095_CR19","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/ki.2008.180","volume":"74","author":"J Jokihaara","year":"2008","unstructured":"Jokihaara J, P\u00f6rsti IH, K\u00f6\u00f6bi P, Jolma PM, Mustonen JT, Saha HH, Siev\u00e4nen H, Kannus P, Iwaniec UT, Turner RT, J\u00e4rvinen TL (2008) Treatment of experimental renal osteodystrophy with pamidronate. Kidney Int 74:319\u2013327","journal-title":"Kidney Int"},{"key":"1095_CR20","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/ki.2008.646","volume":"75","author":"KA Lomashvili","year":"2009","unstructured":"Lomashvili KA, Monier-Faugere M-C, Wang X, Malluche HH, O'Neill WC (2009) Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure. Kidney Int 75:617\u2013625","journal-title":"Kidney Int"},{"key":"1095_CR21","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00467-010-1660-5","volume":"26","author":"D-C Fischer","year":"2010","unstructured":"Fischer D-C, Jensen C, Rahn A, Salewski B, Kundt G, Behets GJ, D'Haese P, Haffner D (2010) Ibandronate affects bone growth and mineralization in rats with normal and reduced renal function. Pediatr Nephrol 26:111\u2013117","journal-title":"Pediatr Nephrol"},{"key":"1095_CR22","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s00198-012-2103-x","volume":"24","author":"MR Allen","year":"2012","unstructured":"Allen MR, Chen NX, Gattone VH II, Chen X, Carr AJ, LeBlanc P, Brown D, Moe SM (2012) Skeletal effects of zoledronic acid in an animal model of chronic kidney disease. Osteoporos Int 24:1471\u20131481","journal-title":"Osteoporos Int"},{"key":"1095_CR23","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/jbmr.2089","volume":"29","author":"SM Moe","year":"2014","unstructured":"Moe SM, Chen NX, Newman CL, Gattone VH II, Organ JM, Chen X, Allen MR (2014) A comparison of calcium to zoledronic acid for improvement of cortical bone in an animal model of CKD. J Bone Miner Res 29:902\u2013910","journal-title":"J Bone Miner Res"},{"key":"1095_CR24","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1681\/ASN.2005010052","volume":"16","author":"O Gutierrez","year":"2005","unstructured":"Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, J\u00fcppner H, Wolf M (2005) Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 16:2205\u20132215","journal-title":"J Am Soc Nephrol"},{"key":"1095_CR25","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/ki.2010.313","volume":"78","author":"H Hasegawa","year":"2010","unstructured":"Hasegawa H, Nagano N, Urakawa I, Yamazaki Y, Iijima K, Fujita T, Yamashita T, Fukumoto S, Shimada T (2010) Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int 78:975\u2013980","journal-title":"Kidney Int"},{"key":"1095_CR26","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/ki.2009.466","volume":"77","author":"H Komaba","year":"2010","unstructured":"Komaba H, Fukagawa M (2010) FGF23\u2014parathyroid interaction: implications in chronic kidney disease. Kidney Int 77:292\u2013298","journal-title":"Kidney Int"},{"key":"1095_CR27","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1046\/j.1523-1755.2000.00259.x","volume":"58","author":"A Felsenfeld","year":"2000","unstructured":"Felsenfeld A, Jara A, Avedian G, Kleeman C (2000) Effects of fasting, feeding, and bisphosphonate administration on serum calcitriol levels in phosphate-deprived rats. Kidney Int 58:1016\u20131022","journal-title":"Kidney Int"},{"key":"1095_CR28","first-page":"E260","volume":"254","author":"J-P Bonjour","year":"1988","unstructured":"Bonjour J-P, Treschel U, Taylor CM, Fleisch H (1988) Parathyroid hormone-independent regulation of 1,25(OH)2D in response to inhibition of bone resorption. Am J Physiol 254:E260\u2013E264","journal-title":"Am J Physiol"},{"key":"1095_CR29","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/S0006-291X(05)81319-1","volume":"180","author":"Y Nagao","year":"1991","unstructured":"Nagao Y, Ishitobi Y, Kinoshita H, Fukushima S, Kawashima H (1991) YM175, a new bisphosphonate, increases serum 1,25-dihydroxyvitamin D in rats via stimulating renal 1-hydroxylase activity. Biochem Biophys Res Commun 180:1172\u20131178","journal-title":"Biochem Biophys Res Commun"},{"key":"1095_CR30","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.bone.2006.02.054","volume":"39","author":"M Ito","year":"2006","unstructured":"Ito M, Nakayama K, Konaka A, Sakata K, Ikeda K, Maruyama T (2006) Effects of a prostaglandin EP4 agonist, ONO-4819, and risedronate on trabecular microstructure and bone strength in mature ovariectomized rats. Bone 39:453\u2013459","journal-title":"Bone"},{"key":"1095_CR31","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/jbmr.1805","volume":"28","author":"DW Dempster","year":"2013","unstructured":"Dempster DW, Compston JE, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR, Parfitt AM (2013) Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 28:2\u201317","journal-title":"J Bone Miner Res"},{"key":"1095_CR32","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/ndt\/gfi273","volume":"21","author":"K Tamagaki","year":"2006","unstructured":"Tamagaki K, Yuan Q, Ohkawa H, Imazeki I, Moriguchi Y, Imai N, Sasaki S, Takeda K, Fukagawa M (2006) Severe hyperparathyroidism with bone abnormalities and metastatic calcification in rats with adenine-induced uraemia. Nephrol Dial Transplant 21:651\u2013659","journal-title":"Nephrol Dial Transplant"},{"key":"1095_CR33","doi-asserted-by":"crossref","first-page":"F1315","DOI":"10.1152\/ajprenal.00552.2009","volume":"298","author":"JL Finch","year":"2010","unstructured":"Finch JL, Tokumoto M, Nakamura H, Yao W, Shahnazari M, Lane N, Slatopolsky E (2010) Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease. Am J Physiol Renal Physiol 298:F1315\u2013F1322","journal-title":"Am J Physiol Renal Physiol"},{"key":"1095_CR34","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.bone.2010.04.600","volume":"47","author":"I Nikolov","year":"2010","unstructured":"Nikolov I, Joki N, Nguyen-Khoa T, Ivanovski O, Phan O, Lacour B, Dr\u00fceke TB, Massy ZA, Dos Reis LM, Jorgetti V, Lafage-Proust MH (2010) Chronic kidney disease bone and mineral disorder (CKD\u2013MBD) in apolipoprotein E-deficient mice with chronic renal failure. Bone 47:156\u2013163","journal-title":"Bone"},{"key":"1095_CR35","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.kint.2017.02.014","volume":"92","author":"H Komaba","year":"2017","unstructured":"Komaba H, Kaludjerovic J, Hu D, Nagano K, Amano K, Ide N, Sato T, Densmore MJ, Hanai JI, Olauson H, Bellido T, Larsson TE, Baron R, Lanske B (2017) Klotho expression in osteocytes regulates bone metabolism and controls bone formation. Kidney Int 92:599\u2013611","journal-title":"Kidney Int"},{"key":"1095_CR36","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00784-010-0477-8","volume":"16","author":"F Koch","year":"2012","unstructured":"Koch F, Merkel C, Ziebart T, Smeets R, Walter C, Al-Nawas B (2012) Influence of bisphosphonates on the osteoblast RANKL and OPG gene expression in vitro. Clin Oral Invest 16:79\u201386","journal-title":"Clin Oral Invest"},{"key":"1095_CR37","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000183355","volume":"39","author":"B Lindergard","year":"1985","unstructured":"Lindergard B, Johnell O, Nilsson BE, Wiklund PE (1985) Studies of bone morphology, bone densitometry and laboratory data in patients on maintenance hemodialysis treatment. Nephron 39:122\u2013129","journal-title":"Nephron"},{"key":"1095_CR38","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1002\/jbmr.1916","volume":"28","author":"T Nickolas","year":"2013","unstructured":"Nickolas T, Stein E, Dworakowski E, Nishiyama KK, Komandah-Kosseh M, Zhang CA, McMahon DJ, Liu XS, Boutroy S, Cremers S, Shane E (2013) Rapid cortical bone loss in patients with chronic kidney disease. J Bone Miner Res 28:1811\u20131820","journal-title":"J Bone Miner Res"},{"key":"1095_CR39","doi-asserted-by":"crossref","first-page":"4074","DOI":"10.1210\/en.2005-0480","volume":"146","author":"S Lotinun","year":"2005","unstructured":"Lotinun S, Sibonga JD, Turner RT (2005) Evidence that the cells responsible for marrow fibrosis in a rat model for hyperparathyroidism are preosteoblasts. Endocrinology 146:4074\u20134081","journal-title":"Endocrinology"},{"key":"1095_CR40","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1525-139X.2007.00300.x","volume":"20","author":"KA Hruska","year":"2007","unstructured":"Hruska KA, Saab G, Mathew S, Lund R (2007) Renal osteodystrophy, phosphate homeostasis, and vascular calcification. Semin Dial 20:309\u2013315","journal-title":"Semin Dial"},{"key":"1095_CR41","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1002\/jbmr.5650091115","volume":"9","author":"DD Bikle","year":"1994","unstructured":"Bikle DD, Morey-Holton ER, Doty SB, Currier PA, Tanner SJ, Halloran BP (1994) Alendronate increases skeletal mass of growing rats during unloading by inhibiting resorption of calcified cartilage. J Bone Miner Res 9:1777\u20131787","journal-title":"J Bone Miner Res"},{"key":"1095_CR42","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.bone.2006.05.006","volume":"39","author":"K Iwata","year":"2006","unstructured":"Iwata K, Li J, Follet H, Phipps RJ, Burr DB (2006) Bisphosphonates suppress periosteal osteoblast activity independently of resorption in rat femur and tibia. Bone 39:1053\u20131058","journal-title":"Bone"},{"key":"1095_CR43","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00418-016-1450-7","volume":"146","author":"K Tsuboi","year":"2016","unstructured":"Tsuboi K, Hasegawa T, Yamamoto T, Sasaki M, Hongo H, de Freitas PH, Shimizu T, Takahata M, Oda K, Michigami T, Li M, Kitagawa Y, Amizuka N (2016) Effects of drug discontinuation after short-term daily alendronate administration on osteoblasts and osteocytes in mice. Histochem Cell Biol 146:337\u2013350","journal-title":"Histochem Cell Biol"},{"key":"1095_CR44","first-page":"6001","volume":"60","author":"GG Reinholz","year":"2000","unstructured":"Reinholz GG, Getz B, Pederson L, Sanders ES, Subramaniam M, Ingle JN, Spelsberg TC (2000) Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res 60:6001\u20136007","journal-title":"Cancer Res"},{"key":"1095_CR45","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1016\/j.biomaterials.2003.11.024","volume":"25","author":"GI Im","year":"2004","unstructured":"Im GI, Qureshi SA, Kenney J, Rubash HE, Shanbhag AS (2004) Osteoblast proliferation and maturation by bisphosphonates. Biomaterials 25:4105\u20134115","journal-title":"Biomaterials"},{"key":"1095_CR46","first-page":"69","volume":"1","author":"SE Papapoulos","year":"1986","unstructured":"Papapoulos SE, Harinck HI, Bijvoet OL, Gleed JH, Fraher LJ, O'Riordan JL (1986) Effects of decreasing serum calcium on circulating parathyroid hormone and vitamin D metabolites in normocalcaemic and hypercalcaemic patients treated with APD. Bone Miner 1:69\u201378","journal-title":"Bone Miner"},{"key":"1095_CR47","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/BF02411260","volume":"34","author":"S Adami","year":"1982","unstructured":"Adami S, Frijlink WB, Bijvoet OL, O'Riordan JL, Clemens TL, Papapoulos SE (1982) Regulation of calcium absorption by 1,25-dihydroxy-vitamin D: studies of the effects of a bisphosphonate treatment. Calcif Tissue Int 34:317\u2013320","journal-title":"Calcif Tissue Int"},{"key":"1095_CR48","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","volume":"121","author":"C Faul","year":"2011","unstructured":"Faul C, Amaral A, Oskouei B, Hu MC, Sloan A et al (2011) FGF23 induces left ventricular hypertrophy. J Clin Invest 121:4393\u20134408","journal-title":"J Clin Invest"},{"key":"1095_CR49","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.kint.2016.05.019","volume":"90","author":"S Singh","year":"2016","unstructured":"Singh S, Grabner A, Yanucil C, Schramm K, Czaya B, Krick S, Czaja MJ, Bartz R, Abraham R, Di Marco GS, Brand M, Wolf M, Faul C (2016) Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. Kidney Int 90:985\u2013996","journal-title":"Kidney Int"},{"key":"1095_CR50","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1172\/JCI83470","volume":"126","author":"J Rossaint","year":"2016","unstructured":"Rossaint J, Oehmichen J, Van Aken H, Reuter S, Pavenst\u00e4dt HJ, Meersch M, Unruh M, Zarbock A (2016) FGF23 signaling impairs neutrophil recruitment and host defense during CKD. J Clin Invest 126:962\u2013974","journal-title":"J Clin Invest"},{"key":"1095_CR51","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1046\/j.1365-2125.2000.00135.x","volume":"49","author":"DY Mitchell","year":"2000","unstructured":"Mitchell DY, St Peter JV, Eusebio RA, Pallone KA, Kelly SC, Russell DA, Nesbitt JD, Thompson GA, Powell JH (2000) Effect of renal function on risedronate pharmacokinetics after a single oral dose. Br J Clin Pharmacol 49:215\u2013222","journal-title":"Br J Clin Pharmacol"},{"key":"1095_CR52","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s11914-017-0361-4","volume":"15","author":"M Allen","year":"2017","unstructured":"Allen M, Aref M (2017) What animal models have taught us about the safety and efficacy of bisphosphonates in chronic kidney disease. Curr Osteoporos Rep 15:171\u2013177","journal-title":"Curr Osteoporos Rep"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-020-01095-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00774-020-01095-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-020-01095-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T01:06:59Z","timestamp":1614906419000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00774-020-01095-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,5]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["1095"],"URL":"https:\/\/doi.org\/10.1007\/s00774-020-01095-0","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,5]]},"assertion":[{"value":"18 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Komaba has received honoraria, consulting fees, and\/or grant support from Bayer Yakuhin, Chugai Pharmaceutical, Japan Tobacco, Kyowa Kirin, Novartis, and Ono Pharmaceutical. Dr. Wada has received honoraria, consulting fees, and\/or grant support from Chugai Pharmaceutical, Daiichi Sankyo, Kyowa Kirin, and Otsuka Pharmaceutical. Dr. Nakamura received grant support from Astellas Pharma and Novartis. Dr. Fukagawa has received honoraria, consulting fees, and\/or grant support from Astellas Pharma, Bayer Yakuhin, EA Pharma Co., Ltd., Kissei Pharmaceutical, Kyowa Kirin, Ono Pharmaceutical, and Torii Pharmaceutical. The remaining authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All experiments were approved by the Institutional Review Board of Tokai University School of Medicine.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}